Molecular Partners AG (MOLN) stock

MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 1/30

$2.94−0.07 (-2.33%)

Close on Nov 13, 2026Market cap $118.70MP/E –Yield –

Molecular Partners pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Molecular Partners's pe ratio was 1.1× on Feb 29, 2024.

Period	Period end	Value	Change (pts)
2024	Feb 29, 2024	1.1×	+0.1
2023	Dec 29, 2023	1.0×	–

Parsed from the XBRL in Molecular Partners's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MOLN.

Revenue growth-100.0% · median -7.3%

Advertisement
300 × 250

See a number that looks wrong?